Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients

<b>Background:</b> The emergence of checkpoint inhibitors (CPIs) has significantly improved survival outcomes in later-stage melanoma. However, the efficacy of these treatments remains limited, with around 50% of later-stage melanoma patients experiencing recurrence. As variable response...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Joseph C. Broderick, Alexandra M. Adams, Elizabeth L. Barbera, Spencer Van Decar, Guy T. Clifton, George E. Peoples
Formaat: Artikel
Taal:Engels
Gepubliceerd in: MDPI AG 2025-06-01
Reeks:Vaccines
Onderwerpen:
Online toegang:https://www.mdpi.com/2076-393X/13/6/656
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!